A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.

about

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.

Item

http://www.wikidata.org/entity/Q38607635

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.

@en

type

Item

label

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.

@en

prefLabel

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.

@en

P1476

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.

@en

P2093

Alan Winston

http://www.w3.org/2001/XMLSchema#string

Alfredo Nicosia

http://www.w3.org/2001/XMLSchema#string

Cinzia Traboni

http://www.w3.org/2001/XMLSchema#string

Deborah Ashby

http://www.w3.org/2001/XMLSchema#string

Georgios Bouliotis

http://www.w3.org/2001/XMLSchema#string

Jonathan Weber

http://www.w3.org/2001/XMLSchema#string

Killian Quinn

http://www.w3.org/2001/XMLSchema#string

Nicki Doyle

http://www.w3.org/2001/XMLSchema#string

Riccardo Cortese

http://www.w3.org/2001/XMLSchema#string

Saye Khoo

http://www.w3.org/2001/XMLSchema#string

P2860

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity

Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.

Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment.

Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry

Viral entry inhibitors targeted to the membrane site of action.

Lipid composition and fluidity of the human immunodeficiency virus.

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.

P2888

s41598-017-09230-0

P304

9447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-09230-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonello Pessi

P577

2017-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091298635

http://www.w3.org/2001/XMLSchema#string

P698

28842581

http://www.w3.org/2001/XMLSchema#string

P932

5572697

http://www.w3.org/2001/XMLSchema#string